1
Comment on paper by Ahikari, Ozeki, Tomida, akurai, Tamai, Ogura: retention of dye after indocyanine-green aited internal limiting membrane peeling, and by Ciardella, chiff, Barile, Vidne, parrow, Langton, Chang: peritent indocyanine green fluorecence aft
36
Comment on the article “Morphodynamic classification of sandy beaches in low energetic marine environment” by Gómez-Pujol, L., Orfila, A., Cañellas, B., Alvarez-Ellacuria, A., Méndez, F.J., Medina, R. and Tintoré, J. Marine Geology, 242, pp. 235–246, 2007
95
Comment on the paper of de Ignacio, C., Muñoz, M., Sagredo, J., Fernández-Santín, S. and Johansson, A., 2006. Isotope geochemistry and FOZO mantle component of the alkaline–carbonatitic association of Fuerteventura, Canary Islands, Spain. Chem. Geol. 232,
183
Comment on: ‘A late Pleistocene clockwise rotation phase of Zakynthos (Greece) and implications for the evolution of the western Aegean Arc’: By Duermeijer, C.E., Krijgsman, W., Langereis, C.G., Meulenkamp, J.E., Triantaphyllou, M.V., Zachariasse, W.J., E
213
Comment on: “Cobeñas, G., Thouret, J.-C., Bonadonna, C., Boivin, P., 2012. The c.2030 yr BP Plinian eruption of El Misti volcano, Peru: Eruption dynamics and hazard implications. Journal of Volcanology and Geothermal Research 241-242, 105-120.”
324
Comment on: Geochemical and isotopic (Sr, U) variations of lake waters in the Ol’khon Region, Siberia, Russia: Origin and paleoenvironmental implications by F. Chabaux, M. Granet, P. Larqué, J. Riotte, E.V. Skliarov, O. Skliarova, L. Alexeieva, F. Risache
338
Comment on: Orbital cyclostratigraphy of the Devonian Frasnian–Famennian transition in South China, by Gong, Y.M., Li, B.H., Wang, Y., Wu, Y., Palaeogeogr. Palaeoclimatol. Palaeoecol. 168 (2001), 237–248
516
Commentary on “70 Gy vs. 80 Gy in localized prostate cancer: 5-Year results of GETUG 06 randomized trial.” Beckendorf V, Guerif S, Le Prisé E, Cosset JM, Bougnoux A, Chauvet B, Salem N, Chapet O, Bourdain S, Bachaud JM, Maingon P, Hannoun-Levi JM, Malissa
517
Commentary on “A comparison of outcomes for interfascial and intrafascial nerve-sparing radical prostatectomy”: Stolzenburg JU, Kallidonis P, Do M, Dietel A, Häfner T, Rabenalt R, Sakellaropoulos G, Ganzer R, Paasch U, Horn LC, Liatsikos E, Department of
522
Commentary on “A non-cancer-related survival benefit is associated with partial nephrectomy.” Sun M, Trinh QD, Bianchi M, Hansen J, Hanna N, Abdollah F, Shariat SF, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI, Cancer Prognostics and Health Outcomes
530
Commentary on “Abiraterone in metastatic prostate cancer without previous chemotherapy.” Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijv
531
Commentary on “Abiraterone in metastatic prostate cancer without previous chemotherapy.” Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijv
533
Commentary on “Adverse prognostic factors for testicular cancer-specific survival: A population-based study of 27,948 patients.” Fosså SD, Cvancarova M, Chen L, Allan AL, Oldenburg J, Peterson DR, Travis LB, Oslo University Hospital, University of Oslo, N
538
Commentary on “Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial.” Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakow
539
Commentary on “Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial.” Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakow
549
Commentary on “Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.” Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan
550
Commentary on “Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.” Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan
553
Commentary on “Circulating angiostatin, bFGF, and Tie2/TEK levels and their prognostic impact in bladder cancer.” Szarvas T, Jäger T, Laszlo V, Kramer G, Klingler HC, vom Dorp F, Romics I, Ergün S, Rübben H, Department of Urology, University of Duisburg-E
555
Commentary on “Common Genetic Polymorphisms Modify the Effect of Smoking on Absolute Risk of Bladder Cancer.” Garcia-Closas M, Rothman N, Figueroa JD, Prokunina-Olsson L, Han SS, Baris D, Jacobs EJ, Malats N, De Vivo I, Albanes D, Purdue MP, Sharma S, Fu
558
Commentary on “Comparative effectiveness of cryotherapy vs. brachytherapy for localized prostate cancer.” Williams SB, Lei Y, Nguyen PL, Gu X, Lipsitz SR, Yu HY, Kowalczyk KJ, Hu JC, Division of Urologic Surgery, Department of Radiation Oncology, Center f
572
Commentary on “Detailed analysis of morbidity following nephrectomy for renal cell carcinoma in octogenarians.” Berger J, Fardoun T, Brassart E, Capon G, Bigot P, Bernhard JC, Rigaud J, Patard JJ, Descazeaud A, Department of Urology, Dupuytren University
573
Commentary on “Detailed analysis of morbidity following nephrectomy for renal cell carcinoma in octogenarians.” Berger J, Fardoun T, Brassart E, Capon G, Bigot P, Bernhard JC, Rigaud J, Patard JJ, Descazeaud A, Department of Urology, Dupuytren University
579
Commentary on “Dynamic real-time microscopy of the urinary tract using confocal laser endomicroscopy.” Wu K, Liu JJ, Adams W, Sonn GA, Mach KE, Pan Y, Beck AH, Jensen KC, Liao JC, Department of Urology, Stanford Cancer Center, Stanford University School o
584
Commentary on “Effects of prostate-specific antigen testing on familial prostate cancer risk estimates”: Bratt O, Garmo H, Adolfsson J, Bill-Axelson A, Holmberg L, Lambe M, Stattin P, Department of Urology, Helsingborg Hospital, Helsingborg, Sweden. J Nat
586
Commentary on “ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients.” Baena E, Shao Z, Linn DE, Glass K, Hamblen MJ, Fujiwara Y, Kim J, Nguyen M, Zhang X, Godinho FJ, Bronson RT, Mucci LA, Loda M, Yuan GC,
592
Commentary on “Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival”. Nguyen PL, Ma J, Chavarro JE, Freedman ML, Lis R, Fedele G, Fiore C, Qiu W, Fiorentino M, Finn S, Penney KL, Eisenstein A, Schumacher
593
Commentary on “Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery.” Silberstein JL, Millard F, Mehrazin R, Kopp R, Bazzi W, DiBlasio CJ, Patterson AL, Downs TM, Yunus F, Kane CJ, Derweesh IH, Division of Urology, Department o
605
Commentary on “Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.” Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S,
607
Commentary on “Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy.” Campeggi A, Xylinas E, Ploussard G, Ouzaid I, Fabre A, Allory Y, Vordos D, Abbou CC, Salom
608
Commentary on “Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy.” Campeggi A, Xylinas E, Ploussard G, Ouzaid I, Fabre A, Allory Y, Vordos D, Abbou CC, Salom
609
Commentary on “Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death”. Choueiri TK, Chen MH, DʹAmico AV, Sun L, Nguyen PL, Hayes JH, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul
614
Commentary on “Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer.” Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, Jäger
615
Commentary on “Intermittent versus continuous androgen deprivation in prostate cancer.” Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN,
616
Commentary on “Intermittent versus continuous androgen deprivation in prostate cancer.” Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN,
617
Commentary on “Intermittent versus continuous androgen deprivation in prostate cancer.” Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN,
627
Commentary on “Locally advanced prostate cancer: A population-based study of treatment patterns”. W.T. Lowrance, E.B. Elkin, D.S. Yee, A. Feifer, B. Ehdaie, L.M. Jacks, C.L. Atoria, M.J. Zelefsky, H.I. Scher, P.T. Scardino, J.A. Eastham, Department of Sur
630
Commentary on “Management of rectal injury during robotic radical prostatectomy.” Kheterpal E, Bhandari A, Siddiqui S, Pokala N, Peabody J, Menon M, Vattikuti Urology Institute, Henry Ford Health System, Henry Ford Hospital, Detroit, Michigan: Urology 201
635
Commentary on “Mortality results from the Göteborg randomized population-based prostate-cancer screening trial”: Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H, Department of Urology, Institute of
637
Commentary on “Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: A phase II study”. Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA, Department of Genitourinary M
645
Commentary on “Outcomes of robotic partial nephrectomy for renal masses with nephrometry score of ≥7.” White MA, Haber GP, Autorino R, Khanna R, Hernandez AV, Forest S, Yang B, Altunrende F, Stein RJ, Kaouk JH, Department of Surgery, Center for Laparoscop
646
Commentary on “Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy.” Lu Z, Yeh TK, Wang J, Chen L, Lyness G, Xin Y, Wientjes MG, Bergdall V, Couto G, Alvarez-Berger F, Kosarek CE, Au JL, Optimum Therapeutics, L.L.C., Columbus, OH: J U
650
Commentary on “Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer.” Gray PJ, Paly JJ, Yeap BY, Sanda MG, Sandler HM, Michalski JM, Talcott JA, Coen JJ, Hamstra DA, Shiple
655
Commentary on “Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.” Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G, University of Pennsylvania,
656
Commentary on “Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.” Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G, University of Pennsylvania,
657
Commentary on “Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04–75.” Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Wad
664
Commentary on “Predicting metastasized seminoma using gene expression.” Ruf CG, Linbecker M, Port M, Riecke A, Schmelz HU, Wagner W, Meineke V, Abend M, Department of Urology, Federal Armed Forces Hospital, Hamburg, Germany : BJU Int 2012;110:E14
665
Commentary on “Predicting metastasized seminoma using gene expression.” Ruf CG, Linbecker M, Port M, Riecke A, Schmelz HU, Wagner W, Meineke V, Abend M, Department of Urology, Federal Armed Forces Hospital, Hamburg, Germany : BJU Int 2012;110:E14
672
Commentary on “Prognostic significance of undetectable ultrasensitive prostate-specific antigen nadir after radical prostatectomy”: Hong SK, Park HZ, Lee WK, Kim DS, Lee JS, Doo SH, Jeong SJ, Yoon CY, Byun SS, Lee SE, Department of Urology, Seoul National
674
Commentary on “Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: Mortality results after 13 years of follow-up”. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Isaacs
681
Commentary on “Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and Ki67 labeling in prostate cancer patients.” Wagner D, Trudel D, Van der Kwast T, Nonn L, Giangreco AA, Li D, Dias A, Cardoza M, Laszlo S, Hersey K, K
682
Commentary on “Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and Ki67 labeling in prostate cancer patients.” Wagner D, Trudel D, Van der Kwast T, Nonn L, Giangreco AA, Li D, Dias A, Cardoza M, Laszlo S, Hersey K, K
685
Commentary on “Reproductive factors and kidney cancer risk in 2 US cohort studies, 1993-2010.” Karami S, Daugherty SE, Schonfeld SJ, Park Y, Hollenbeck AR, Grubb RL 3rd, Hofmann JN, Chow WH, Purdue MP, Occupational and Environmental Epidemiology Branch, D
690
Commentary on “Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome.” Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, Parry S, Goldblatt J, Lipton L, Winship I, Leggett B, Tucker KM, Giles GG, Buchanan DD, Cl
691
Commentary on “Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome.” Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, Parry S, Goldblatt J, Lipton L, Winship I, Leggett B, Tucker KM, Giles GG, Buchanan DD, Cl
702
Commentary on “Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study.” Schutz FA, Pomerantz MM, Gray KP, Atkins MB, Rosenberg JE, Hirsch MS, McDermott DF, Lampron ME, Lee GS, Signoretti S, Kantoff PW, Freedman ML,
703
Commentary on “Sipuleucel-T immunotherapy for castration-resistant prostate cancer”. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigator
705
Commentary on “Smoking negatively affects renal cell carcinoma overall and cancer-specific survival.” Kroeger N, Klatte T, Birkhäuser FD, Rampersaud EN, Seligson DB, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ, Institute of Urologic Oncology, D
719
Commentary on “Testicular cancer survivorship: Research strategies and recommendations”. Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, Daugaard G, Kelly JL, Dolan ME, Hannigan R, Constine LS, Oeffinger KC, Okunieff P, Armstrong G, Wiljer
723
Commentary on “The clinical epidemiology of urachal carcinoma: Results of a large, population based study.” Bruins HM, Visser O, Ploeg M, Hulsbergen-van de Kaa CA, Kiemeney LA, Witjes JA, Department of Urology, Radboud University Medical Centre, Utrecht,
724
Commentary on “The clinical epidemiology of urachal carcinoma: Results of a large, population based study.” Bruins HM, Visser O, Ploeg M, Hulsbergen-van de Kaa CA, Kiemeney LA, Witjes JA, Department of Urology, Radboud University Medical Centre, Utrecht,
751
Commentary on “Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.” Choueiri TK, Lim ZD, Hirsch, MS, Tamboli P, Jonasch E, McDermott DF, Dal Cin P, Corn P, Vaishampayan U, He
766
Commentary on Bevacizumab plus interferonα compared with interferonα monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206: Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutch
774
Commentary on Circulating microRNAs as stable blood-based markers for cancer detection: Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, OʹBriant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen, Stire
780
Commentary on Cumulative association of five genetic variants with prostate cancer: Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Bنlter K, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Duggan D, Carpten JD, Chang BL
797
Commentary on Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomized phase III trial: Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklu
798
Commentary on Essential roles of PI(3)K-p110β in cell growth, metabolism, and tumorigenesis: Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ, Department of Cancer Biology, Dana-Farber Cancer Institute, Bos
806
Commentary on Flexible robotic retrograde renoscopy: Description of novel robotic device and preliminary laboratory experience: Desai MM, Aron M, Gill IS, Pascal-Haber G, Ukimura O, Kaouk JH, Stahler G, Barbagli F, Carlson C, Moll F, Section of Laparoscop
808
Commentary on Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer: Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kuma
811
Commentary on High-intensity focused ultrasound for prostate cancer: Comparative definitions of biochemical failure: Blana A, Brown SC, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Pasticier G, Rebillard X, Rewcastle JC, Robertson CN, Thuroff S, W
828
Commentary on Laboratory evaluation of laparoscopic vascular clamps using a load-cell device—are all clamps the same?: Lee HJ, Box GN, Abraham JB, Elchico ER, Panah RA, Taylor MB, Moskowitz R, Deane LA, McDougall EM, Clayman RV, Department of Urology, Uni
829
Commentary on Lack of comprehension of common prostate cancer terms in an underserved population: Kilbridge KL, Fraser G, Krahn M, Nelson EM, Conaway M, Bashore R, Wolf A, Barry MJ, Gong DA, Nease RF Jr., Connors AF, Massachusetts General Hospital, Genera
843
Commentary on Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis: Liang XJ, Meng H, Wang Y, He H, Meng J, Lu J, Wang PC, Zhao Y, Gao X, Sun B, Chen C, Xing G, Shen D, Gottesman MM, Wu Y, Yin JJ, Jia L, Chin
847
Commentary on Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer: Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, Nielsen ME, Müller SC, Riga
861
Commentary on Pelvic Lymph Node Dissection in Prostate Cancer: Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, Montorsi F, Studer UE, Department of Urology, Vita-Salute University, Milan, Italy
864
Commentary on Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer: Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz LH, Scher HI, Genitourinary
872
Commentary on Prostate cancer severity among low income, uninsured men: Miller DC, Litwin MS, Bergman J, Stepanian S, Connor SE, Kwan L, Aronson WJ, Department of Urology, University of California, Los Angeles, CA
878
Commentary on Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis: Xie D, Gore C, Liu J, Pong RC, Mason R, Hao G, Long M, Kabbani W, Yu L, Zhang H, Chen H, Sun X, Boothman DA, Min W, Hsieh JT, Department of Uro
882
Commentary on Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded-access trial: Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schِffski P, Mainwarin
885
Commentary on Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer: Attard G, Reid AH, AʹHern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D
891
Commentary on Specific reduction of Fas-associated protein with death domain (FADD) in clear cell renal cell carcinoma: Xu H, He L, Feng X, Kapoor A, Tang D, Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China
895
Commentary on Surgery for metastatic urothelial carcinoma with curative intent: The German experience (AUO AB 30/05): Lehmann J, Suttmann H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Gr
896
Commentary on Surgical resection of renal cell carcinoma after targeted therapy: Thomas AA, Rini BI, Stephenson AJ, Garcia JA, Fergany A, Krishnamurthi V, Novick AC, Gill IS, Klein EA, Zhou M, Campbell SC, Glickman Urological and Kidney Institute, Clevela
897
Commentary on Surgical salvage of renal cell carcinoma recurrence after thermal ablative therapy: Nguyen CT, Lane BR, Kaouk JH, Hegarty N, Gill IS, Novick AC, Campbell SC, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, O
901
Commentary on Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model: Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen
904
Commentary on Testis-sparing surgery versus radical orchiectomy in patients with Leydig cell tumors: Loeser A, Vergho DC, Katzenberger T, Brix D, Kocot A, Spahn M, Gerharz EW, Riedmiller H, Department of Urology, Institute of Pathology, Julius-Maximilians
935
Commentary on Transcriptome sequencing to detect gene fusions in cancer: Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, Sam L, Barrette T, Palanisamy N, Chinnaiyan AM, Michigan Center for Translational Pathology, Ann Arbor, MI
936
Commentary on Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma: Verhoest G, Avakian R, Bensalah K, Thuret R, Ficarra V, Artibani W, Tostain J, Guille F, Cindolo L, De La Taille A, Abbou CC, Salo
938
Commentary on Use of high fidelity operating room simulation to assess and teach communication, teamwork, and laparoscopic skills: Initial experience: Gettman MT, Pereira CW, Lipsky K, Wilson T, Arnold JJ, Leibovich BC, Karnes RJ, Dong Y, Departments of U
940
Commentary on Variation in KLK genes, prostate-specific antigen and risk of prostate cancer: Ahn J, Berndt SI, Wacholder S, Kraft P, Kibel AS, Yeager M, Albanes D, Giovannucci E, Stampfer MJ, Virtamo J, Thun MJ, Feigelson HS, Cancel-Tassin G, Cussenot O,
945
Commentary on: “Blood transfusions in radical prostatectomy: A contemporary population-based analysis”. J. Schmitges, M. Sun, F. Abdollah, Q.D. Trinh, C. Jeldres, L. Budäus, M. Bianchi, J. Hansen, T. Schlomm, P. Perrotte, M. Graefen, P.I. Karakiewicz, Mar
947
Commentary on: “Long-term functional outcomes after treatment for localized prostate cancer.” Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. Department of Urologi